Advertisement

Intravenous oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery: a systematic review and meta-analysis

      Objective

      To compare the available evidence on intravenous oxytocin dosing regimens for the prevention of postpartum hemorrhage following cesarean delivery.

      Data Sources

      We searched Ovid MEDLINE, Embase, Global Index Medicus, Cumulative Index of Nursing and Allied Health Literature, Cochrane Controlled Register of Trials, ClinicalTrials.gov, and the International Clinical Trials Registry Platform for eligible studies published until February 2020.

      Study Eligibility Criteria

      We included any randomized or nonrandomized study published in peer-reviewed journals that compared at least 2 different dosing regimens of intravenous oxytocin for postpartum hemorrhage prevention in women undergoing cesarean delivery.

      Methods

      Two authors independently assessed the eligibility of studies, extracted the data, and assessed the risk of bias. The primary outcome was incidence of postpartum hemorrhage ≥1000 mL. Other review outcomes included use of additional uterotonics, blood loss, and adverse maternal events. Data were analyzed according to the type of intravenous administration (bolus only, infusion only, or bolus plus infusion) and total oxytocin dose. A meta-analysis was performed on randomized trials and the results were reported as risk ratios or mean differences with 95% confidence intervals. The Grading of Recommendations, Assessment, Development, and Evaluations scale was used to rate the certainty of evidence. Findings from dose-finding trials and nonrandomized studies were reported narratively.

      Results

      A total of 35 studies (7333 women) met our inclusion criteria and included 30 randomized trials and 5 nonrandomized studies. There were limited data available from the trials for most outcomes, and the results were not conclusive. Compared with bolus plus infusion regimens, bolus only regimens probably result in slightly higher mean blood loss (mean difference, 52 mL; 95% confidence interval, 0.4–104 mL; moderate certainty). Among the bolus plus infusion regimens, initial bolus doses <5 IU may reduce nausea (risk ratio, 0.26; 95% confidence interval, 0.11–0.63; low certainty) when compared with doses of 5–9 IU. Total oxytocin doses of 5–9 IU vs total doses of 10–19 IU may increase the use of additional uterotonics (risk ratio, 13.00; 95% confidence interval, 1.75–96.37; low certainty). Effects on other outcomes were generally inconclusive.

      Conclusion

      There are limited data available for comparisons of IV oxytocin regimens for postpartum hemorrhage prevention following cesarean delivery. Bolus plus infusion regimens may lead to minor reductions in mean blood loss and initial bolus doses of <5 IU may minimize nausea. Bolus only regimens of 10 IU vs bolus only regimens of 5 IU may decrease the need for additional uterotonics, however, further comparative trials are required to understand the effects on other key outcomes, particularly hypotension.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Say L.
        • Chou D.
        • Gemmill A.
        • et al.
        Global causes of maternal death: a WHO systematic analysis.
        Lancet Glob Health. 2014; 2: e323-e333
        • World Health Organization
        Trends in maternal mortality: 2000 to 2017: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division.
        World Health Organization, Geneva2019
        • Unterscheider J.
        • Breathnach F.
        • Geary M.
        Standard medical therapy for postpartum hemorrhage.
        in: Arulkumaran S.S. Karoshi M. Keith L.G. Lalonde A.B. B-Lynch C. A comprehensive textbook of postpartum hemorrhage. Sapiens Publishing, London, United Kingdom2012: 355-360
        • World Health Organization
        WHO recommendations: uterotonics for the prevention of postpartum haemorrhage.
        (Available at:) (Accessed Jan. 22, 2020)
        • Gallos I.D.
        • Papadopoulou A.
        • Man R.
        • et al.
        Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.
        Cochrane Database Syst Rev. 2018; 12: CD011689
        • Dyer R.A.
        • Butwick A.J.
        • Carvalho B.
        Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist.
        Curr Opin Anaesthesiol. 2011; 24: 255-261
        • Stephens L.C.
        • Bruessel T.
        Systematic review of oxytocin dosing at caesarean section.
        Anaesth Intensive Care. 2012; 40: 247-252
        • Heesen M.
        • Carvalho B.
        • Carvalho J.C.A.
        • et al.
        International consensus statement on the use of uterotonic agents during caesarean section.
        Anaesthesia. 2019; 74: 1305-1319
      1. MIMS Australia. Oxytocin Apotex. 2018. Available at: https://www-mimsonline-com-au.eu. Accessed April 4, 2020.

        • University of York Centre for Reviews and Dissemination
        Prospero: international prospective register of systematic reviews.
        (Available at:) (Accessed Feb. 12, 2020)
        • Meher S.
        • Cuthbert A.
        • Kirkham J.J.
        • et al.
        Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study.
        BJOG. 2019; 126: 83-93
      2. EndNote. [computer program]. Clarivate Analytics, Philadelphia, PA2013
      3. Covidence systematic review software. Veritas Health Innovation.
        (Available at:) (Accessed Feb. 17, 2020)
        • Sterne J.A.C.
        • Savović J.
        • Page M.J.
        • et al.
        RoB 2: a revised tool for assessing risk of bias in randomised trials.
        BMJ. 2019; 366: l4898
        • Sterne J.A.
        • Hernán M.A.
        • Reeves B.C.
        • et al.
        Robins-I: a tool for assessing risk of bias in non-randomised studies of interventions.
        BMJ. 2016; 355: i4919
      4. Review manager (RevMan) [computer program]. Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen2014
        • Schünemann H.
        • Brożek J.
        • Guyatt G.
        • Oxman A.
        GRADE handbook for grading quality of evidence and strength of recommendations.
        (Available at:) (Accessed Sep. 23, 2020)
      5. Evidence Prime, Inc. GRADEpro GDT: GRADEpro guideline development tool.
        (Available at:)
        gradepro.org
        Date: 2020
        (Accessed Sep. 23, 2020)
        • Santesso N.
        • Glenton C.
        • Dahm P.
        • et al.
        GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions.
        J Clin Epidemiol. 2020; 119: 126-135
        • Görges M.
        • Zhou G.
        • Brant R.
        • Ansermino J.M.
        Sequential allocation trial design in anesthesia: an introduction to methods, modeling, and clinical applications.
        Paediatr Anaesth. 2017; 27: 240-247
        • Bhattacharya S.
        • Ghosh S.
        • Ray D.
        • Mallik S.
        • Laha A.
        Oxytocin administration during cesarean delivery: randomized controlled trial to compare intravenous bolus with intravenous infusion regimen.
        J Anaesthesiol Clin Pharmacol. 2013; 29: 32-35
        • Butwick A.J.
        • Coleman L.
        • Cohen S.E.
        • Riley E.T.
        • Carvalho B.
        Minimum effective bolus dose of oxytocin during elective caesarean delivery.
        Br J Anaesth. 2010; 104: 338-343
        • Cecilia M.
        • Vijayaselvi R.
        • Bansal R.
        • Lakshmi L.
        • Jose R.
        Ten units intravenous oxytocin over 2-4 h is as effective as 30 units over 8-12 h in preventing postpartum hemorrhage after cesarean section: a randomized controlled trial.
        Indian J Pharmacol. 2018; 50: 279-283
        • Derbel M.
        • Mekki D.
        • Riahi A.
        • Dimassi K.
        • Mebazaa M.S.
        • Gara M.F.
        Comparison of two oxytocin administration protocols in elective cesarean section: 5 iu versus 10 iu.
        Tunis Med. 2016; 94: 253-258
        • Duffield A.
        • McKenzie C.
        • Carvalho B.
        • et al.
        Effect of a high-rate versus a low-rate oxytocin infusion for maintaining uterine contractility during elective cesarean delivery: a prospective randomized clinical trial.
        Anesth Analg. 2017; 124: 857-862
        • Ghulmiyyah L.M.
        • Usta I.M.
        • Ghazeeri G.
        • et al.
        Intravenous oxytocin use to decrease blood loss during scheduled Cesarean delivery: a randomized double-blinded controlled trial (OXYTRIAL).
        Am J Perinatol. 2017; 34: 379-387
        • Golparvar M.
        • Esterabi M.
        • Talakoub R.
        • Saryazdi H.H.
        Evaluation of in vivo effects of oxytocin on coagulation of parturient during cesarean delivery by thromboelastography.
        J Res Pharm Pract. 2014; 3: 28-33
        • Güngördük K.
        • Asicioglu O.
        • Celikkol O.
        • Olgac Y.
        • Ark C.
        Use of additional oxytocin to reduce blood loss at elective caesarean section: a randomised control trial.
        Aust N Z J Obstet Gynaecol. 2010; 50: 36-39
        • Jonsson M.
        • Hanson U.
        • Lidell C.
        • Nordén-Lindeberg S.
        ST depression at caesarean section and the relation to oxytocin dose. A randomised controlled trial.
        BJOG. 2010; 117: 76-83
        • Kajendran J.
        • Silva G.R.C.
        • Ranaraja S.K.
        Effects of 5 iu oxytocin bolus and 20 iu oxytocin infusion compared to 5 iu oxytocin bolus and normal saline infusion in the control of blood loss during and after ante-partum lower segment caesarean section: a randomized controlled trial.
        Ceylon Med J. 2017; 62: 121-127
        • Kikutani T.
        • Oshima M.
        • Sugimoto K.
        • Shimada Y.
        Effects of intravenous infusion rate of oxytocin on thoracic epidural pressure in parturients undregoing elective cesarean section.
        J Nippon Med Sch. 2003; 70: 475-479
        • Kim T.S.
        • Bae J.S.
        • Park J.M.
        • Kang S.K.
        Hemodynamic effects of continuous intravenous injection and bolus plus continuous intravenous injection of oxytocin in cesarean section.
        Korean J Anesthesiol. 2011; 61: 482-487
        • King K.J.
        • Douglas M.J.
        • Unger W.
        • Wong A.
        • King R.A.
        Five unit bolus oxytocin at cesarean delivery in women at risk of atony: a randomized, double-blind, controlled trial.
        Anesth Analg. 2010; 111: 1460-1466
        • Kiran S.
        • Anand A.
        • Singh T.
        • Gupta N.
        To estimate the minimum effective dose of oxytocin required to produce adequate uterine tone in women undergoing elective caesarean delivery.
        Egypt J Anaesth. 2013; 29: 161-165
        • Kovacheva V.P.
        • Soens M.A.
        • Tsen L.C.
        A randomized, Double-blinded Trial of a “Rule of Threes” algorithm versus continuous infusion of oxytocin during elective cesarean delivery.
        Anesthesiology. 2015; 123: 92-100
        • Munn M.B.
        • Owen J.
        • Vincent R.
        • Wakefield M.
        • Chestnut D.H.
        • Hauth J.C.
        Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial.
        Obstet Gynecol. 2001; 98: 386-390
        • Murphy D.J.
        • MacGregor H.
        • Munishankar B.
        • McLeod G.
        A randomised controlled trial of oxytocin 5IU and placebo infusion versus oxytocin 5IU and 30IU infusion for the control of blood loss at elective caesarean section--pilot study. ISRCTN 40302163.
        Eur J Obstet Gynecol Reprod Biol. 2009; 142: 30-33
        • Palacio F.J.
        • Morillas F.
        • Ortiz-Gómez J.R.
        • Fornet I.
        • Bermejo L.
        • Cantalejo F.
        [Efficacy of low-dose oxytocin during elective cesarean section].
        Rev Esp Anestesiol Reanim. 2011; 58: 6-10
        • Pinder A.J.
        • Dresner M.
        • Calow C.
        • Shorten G.D.
        • O’Riordan J.
        • Johnson R.
        Haemodynamic changes caused by oxytocin during caesarean section under spinal anaesthesia.
        Int J Obstet Anesth. 2002; 11: 156-159
        • Qian X.W.
        • Drzymalski D.M.
        • Lv C.C.
        • Guo F.H.
        • Wang L.Y.
        • Chen X.Z.
        The ED50 and ED95 of oxytocin infusion rate for maintaining uterine tone during elective caesarean delivery: a dose-finding study.
        BMC Pregnancy Childbirth. 2019; 20: 6
        • Sarna M.C.
        • Soni A.K.
        • Gomez M.
        • Oriol N.E.
        Intravenous oxytocin in patients undergoing elective cesarean section.
        Anesth Analg. 1997; 84: 753-756
        • Sartain J.B.
        • Barry J.J.
        • Howat P.W.
        • McCormack D.I.
        • Bryant M.
        Intravenous oxytocin bolus of 2 units is superior to 5 units during elective caesarean section.
        Br J Anaesth. 2008; 101: 822-826
        • Sheehan S.R.
        • Montgomery A.A.
        • Carey M.
        • et al.
        Oxytocin bolus versus oxytocin bolus and infusion for control of blood loss at elective caesarean section: double blind, placebo controlled, randomised trial.
        BMJ. 2011; 343: d4661
        • Taj A.
        • Ommid M.
        Haemodynamic effects of oxytocin as intravenous bolus or infusion on women undergoing caesarean section.
        JK Sci. 2014; 16: 52-56
        • Tariq M.
        • Syed W.
        Comparison of haemodynamic effect of equivalent dose of oxytocin given as Bolus and in Fusion.
        Pak Armed Forces Med J. 2018; 68: 1517-1521
        • Thomas J.S.
        • Koh S.H.
        • Cooper G.M.
        Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing caesarean section.
        Br J Anaesth. 2007; 98: 116-119
        • Balki M.
        • Ronayne M.
        • Davies S.
        • et al.
        Minimum oxytocin dose requirement after cesarean delivery for labor arrest.
        Obstet Gynecol. 2006; 107: 45-50
        • Carvalho J.C.
        • Balki M.
        • Kingdom J.
        • Windrim R.
        Oxytocin requirements at elective cesarean delivery: a dose-finding study.
        Obstet Gynecol. 2004; 104: 1005-1010
        • George R.B.
        • McKeen D.
        • Chaplin A.C.
        • McLeod L.
        Up-down determination of the ED(90) of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery.
        Can J Anaesth. 2010; 57: 578-582
        • Lavoie A.
        • McCarthy R.J.
        • Wong C.A.
        The ED90 of prophylactic oxytocin infusion after delivery of the placenta during cesarean delivery in laboring compared with nonlaboring women: an up-down sequential allocation dose-response study.
        Anesth Analg. 2015; 121: 159-164
        • Ahmadi F.
        A comparative study on infusion of usual dose of oxytocin and 80 units dose of oxytocin in the prevention of postpartum hemorrhage in cesarean section.
        J Adv Pharm Technol Res. 2018; 9: 102-106
        • Holleboom C.A.G.
        • van Eyck J.
        • Koenen S.V.
        • et al.
        Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands.
        Arch Gynecol Obstet. 2013; 287: 1111-1117
        • Pursche T.
        • Diedrich K.
        • Banz-Jansen C.
        Blood loss after caesarean section: depending on the management of oxytocin application?.
        Arch Gynecol Obstet. 2012; 286: 633-636
        • Terblanche N.
        • Otahal P.
        • Messmer A.
        • et al.
        An observational cohort study of 3 units versus 5 units slow intravenous bolus oxytocin in women undergoing elective caesarean delivery.
        J Physiol Pharmacol. 2017; 68: 547-553
        • Beiranvand S.
        • Karimi A.
        • Vahabi S.
        • Amin-Bidokhti A.
        Comparison of the mean minimum dose of bolus oxytocin for proper uterine contraction during cesarean section.
        Curr Clin Pharmacol. 2019; 14: 208-213
        • McGuinness L.A.
        • Higgins J.P.T.
        Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.
        Res Synth Methods. 2021; 12: 55-61
        • Committee on Practice Bulletins-Obstetrics
        Practice Bulletin No. 183: postpartum hemorrhage.
        Obstet Gynecol. 2017; 130: e168-e186
      6. Prevention and management of postpartum haemorrhage: Green-top Guideline No. 52.
        BJOG. 2017; 124: e106-e149
        • Sentilhes L.
        • Vayssière C.
        • Deneux-Tharaux C.
        • et al.
        Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR).
        Eur J Obstet Gynecol Reprod Biol. 2016; 198: 12-21
        • Leduc D.
        • Senikas V.
        • Lalonde A.B.
        No. 235-active management of the third stage of labour: prevention and treatment of postpartum hemorrhage.
        J Obstet Gynaecol Can. 2018; 40: e841-e855
        • Leung Y.
        • Sgroi J.
        • Vaughan J.
        • et al.
        Management of postpartum haemorrhage (PPH). Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).
        (Available at:) (Accessed Oct. 29, 2020)
        • Langesceter E.
        • Rosseland L.A.
        Maternal hemodynamics during cesarean delivery.
        Acta Obstet Gynecol Scand. 2006; 85: 126